| Literature DB >> 29236069 |
Elena K Schneider1,2, Jian Li3, Tony Velkov4,5.
Abstract
Pandemic influenza is a constant global threat to human health. In particular, the pandemic potential of novel avian influenza viruses such as the H10N7 and H10N8 avian strains, which recently managed to cross the species barrier from birds to humans, are always of great concern as we are unlikely to have any prior immunity. Human and avian isolates of H10 influenza display the ability to rapidly adapt to replication in mammalian hosts. Fortunately, so far there is no evidence of efficient human-to-human transmission of any avian influenza virus. This review examines all of the available clinical and biological data for H10 influenza viruses with an emphasis on hemagglutinin as it is a major viral antigen that determines host range and immunity. The available glycan binding data on the influenza H10 hemagglutinin are discussed in a structure-recognition perspective. Importantly, this review raises the question of whether the emerging novel avian H10 influenza viruses truly represents a threat to global health that warrants close monitoring.Entities:
Keywords: H10; glycan specificity; hemagglutinin; influenza
Year: 2017 PMID: 29236069 PMCID: PMC5748617 DOI: 10.3390/vaccines5040051
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Figure 1Zoonotic transmission of influenza H10 from birds to humans: a potential pandemic pathway.
α2,3 sialyl-glycan specificity of the human A/Jiangxi-Donghu/346/2013 and avian A/green-winged teal/Texas/Y171/2006 H10 HAs.
| Glycan Structure | Reference |
|---|---|
| Neu5Ac(α2-3)Gal(β1-4)Glc (3′SLN) | [ |
| Neu5Ac(α2-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcN (3′SLNLN) | [ |
| NeuAcα(2-3)-Galβ(1-4)-6-O-sulfo-GlcNAcβ-propyl-NH2 | [ |
| NeuAcα(2-3)-Galβ(1-4)-[Fucα(1-3)]-6-O-sulfo-GlcNAcβ-propyl-NH2 | [ |
| Neu5Acα2-3Galβ1-3[6OSO3]GalNAcα | [ |
| Neu5Acα2-3Galβ1-4[6OSO3]GlcNAcβ | [ |
| NeuAcα(2-3)-Galβ(1-3)-6-O-sulfo-GlcNAcβ-propyl-NH2 | [ |
| Neu5Acα2-3Galβ1-3[6OSO3]GlcNAc-propyl-NH2 | [ |
| Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4)GlcNAcβ | [ |
| Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-6)GalNAcα | [ |
| Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-3Galβ1-4GlcNAc 1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc β | [ |
| Neu5Acα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-3)-[Neu5Acα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-Manα(1-3)-[Neu5Acα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-6)]-Manβ(1-4)-GlcNAcβ(1-4)-GlcNAcβ | [ |
| Neu5Acα2-3Galβ1-3GalNAcα | [ |
| Neu5Acα2-3Galβ1-3GlcNAcβ * | [ |
| NeuAcα(2-3)-Galβ(1-3)-GalNAcα-Thr-NH2 | [ |
| NeuAcα(2-3)-Galβ(1-3)-[GlcNAcβ(1-6)]-GalNAcα-Thr-NH2 | [ |
| Neu5Acα2-3Galβ1-4GlcNAcβ | [ |
| Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ | [ |
| Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ | [ |
| NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-[NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-6)]-GalNAcα-Thr-NH2 | [ |
| Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ | [ |
| NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-3)-[NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-6)]-GalNAcα-Thr-NH2 | [ |
| Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ | [ |
| NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-3)-[NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-6)]-Manβ(1-4)-GlcNAcβ(1-4)-GlcNAcβ-Asn-NH2 | [ |
| Neu5Acα2-3Galβ1-3GalNAcα | [ |
| NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-3)-[NeuAcα(2-3)-Galβ(1-4)-GlcNAcβ(1-3)-Galβ(1-4)-GlcNAcβ(1-2)-Manα(1-6)]-Manβ(1-4)-GlcNAcβ(1-4)-GlcNAcβ-Asn-NH2 | [ |
| Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Ga β1-4(Fucα1-3)GlcNAcβ * | [ |
* Low binding observed to the A/Jiangxi-Donghu/346/2013 H10 HA.
Figure 2(Left) Crystallographic structure of the avian H10 HA trimer (PDB ID: 4CYV) [79]. (Right) General architecture of the H10 receptor binding site (RBS). (Bottom) The co-crystallographic complex of the avian H10 HA with the avian receptor LSTa and human receptor analogue 6′-SLN [79]. The bound receptor analogues are shown in stick form. The R137 substitution in the JX346 human isolate is shown.